Company intelligence / Profile preview

Beijing Scitech-MQ Pharmaceuticals Limited

Ownership: Private
Development stage: Phase 2

Overview

The company has three drug candidates approved in China for clinical trials with two drug candidates in Phase I and one drug candidate in Phase II. ST-1703 is in Phase 1/2 for HER2 Positive Solid Tumors, ST-1898 is in Phase 1 for Advanced Malignant Solid Neoplasm, and ST-1839 is in Phase 1 for Thyroid Cancer[3].

Therapeutic areas: GastroenterologyImmunologyDermatologyOncologyNeurologyInfectious Diseases
Modalities: Small molecule drugs
Industry: Biotech

Drug pipeline

8 assets

ST-6280

Preclinical

7 more assets in the full pipeline.

Request access →

Partnerships

Shanghai Oriental HospitalTigermed Equity Investment PartnershipElikon VentureShanghai Moderation Private Investment Fund

Beyond the preview

Go deeper on Beijing Scitech-MQ Pharmaceuticals Limited.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Beijing Scitech-MQ Pharmaceuticals Limited.

Explore the full profile